Why TherapeuticsMD (TXMD) Stock Is Surging Today

NEW YORK (TheStreet) -- TherapeuticsMD  (TXMD) surged Tuesday after FBR Capital initiated coverage on the pharmaceutical company with an "outperform" rating and a $34 price target.

FBR believes the company is well positioned to change the way in which doctors treat women with hormone replacement therapy. TherapeuticsMD's is developing its TX-001 HR for treating post-menopausal vasomotor symptoms such as hot flashes.

The stock was up 15.01% to $4.75 at 10:36 a.m. More than 5.8 million shares had changed hands, compared to the average volume of 1,167,370.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TXMD Price Chart

TXMD Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Analysts' Actions -- Costco, J.C. Penney, Cisco, TherapeuticsMD and More

TherapeuticsMD Rejected by FDA, Delay Could Be Fatal

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

Penn National Gaming, Wynn Resorts: 'Mad Money' Lightning Round

Valuation Is in the Eye of the Buyer: Cramer's 'Mad Money' Recap (Tuesday 4/4/17)